|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03692 HANSOH PHARMA
Nominal 
18.520 +0.260 (+1.424%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 10,103,806 | 7.689% | 9,382,410 | 9,935,141 | 8,690,234 | 8,682,746 |
| Cost of Sales | (1,030,863) | 18.899% | (867,010) | (870,042) | (801,561) | (729,540) |
| Gross Profit | 9,072,943 | 6.547% | 8,515,400 | 9,065,099 | 7,888,673 | 7,953,206 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 3,766,155 | 27.734% | 2,948,428 | 3,300,082 | 3,098,299 | 3,000,925 | |
| Taxation | (488,652) | 33.994% | (364,681) | (587,180) | (529,392) | (444,183) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,277,503 | 26.851% | 2,583,747 | 2,712,902 | 2,568,907 | 2,556,742 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (838,326) | 234.070% | (250,943) | (111,275) | (90,392) | (153,459) |
| Depreciation & Amortisation | 366,381 | 6.320% | 344,602 | 278,467 | 233,274 | 201,554 |
| Directors' Emoluments | 41,912 | 26.534% | 33,123 | 39,608 | 38,207 | 39,937 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 55.000 | 25.000% | 44.000 | 46.000 | 44.000 | 47.000 |
| DPS (cts) | 19.311 | -- | 8.711 | 7.320 | 6.510 | 0.000 |
| Dividend Payout Ratio (%) | 35.110% | -- | 19.797% | 15.913% | 14.795% | -- |
| Cash flow per share ($) | 0.526 | -- | 0.463 | 0.435 | 0.407 | 0.608 |
| NBV per share ($) | 4.347 | -- | 3.824 | 3.382 | 3.020 | 2.253 |
| Remarks: | Real time quote last updated: 22/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,725,525 |
| %Change | 111.470% |
| EPS / (LPS) | RMB 0.460 |
| NBV Per Share (¥) | RMB 4.701 |